Method for modulating or controlling connexin 43(Cx43) level of a cell and reducing arrhythmic risk
View Patent ↗A method of modulating or controlling connexin 43 (Cx43) level of a cell includes inducing mitochondrial reactive oxygen species (ROS) production in the cell.
1. In a cell having a reduced connexin 43 (Cx43) level associated with renin-angiotensin system (RAS) activation, a method of raising the Cx43 level to a normal level, comprising the step of exposing the cell to an effective amount of a mitochondria-targeted antioxidant thereby modulating connexin 43 (Cx43) level.
2. The method of claim 1 , wherein the antioxidant comprises 2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride (MitoTEMPO).
3. The method of claim 1 , wherein the cell comprises a cardiac cell.
4. A method of treating sudden cardiac death (SCD) associated with renin-angiotensin system (RAS) activation in a cell, comprising the step of administering a mitochondria-targeted antioxidant to a human or animal in need thereof to modulate connexin 43 (Cx43) level.
5. The method of claim 4 , wherein the amount of the antioxidant is effective to reduce arrhythmic risk.
6. The method of claim 4 , wherein the amount of the antioxidant is effective to restore the Cx43 to a normal level.
7. The method of claim 4 , wherein the antioxidant restores the Cx43 level to a normal level by reducing or suppressing mitochondrial reactive oxidation species (ROS) production.
8. The method of claim 4 , wherein the antioxidant comprises 2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride (MitoTEMPO).
9. The method of claim 8 , wherein the amount of antioxidant is effective to result in a more than two-fold increase in the Cx43 level.
10. The method of claim 4 , wherein the antioxidant is administered orally or intravenously.
11. The method of claim 4 , wherein the human or animal is suffering from arrhythmia.
12. The method of claim 4 , wherein the antioxidant comprises at least one member selected from the group consisting of a powder, a tablet, a capsule, a solution, a suspension, and an injectable formulation.
13. The method of claim 4 , wherein the cell comprises a cardiac cell.